Dolores Stadtmauer has over 20 years of experience in clinical drug development and pharmaceutical safety. Her experience includes 10 years at Bristol-Myers Squibb as a Safety Regulatory Associate and Clinical Data Examiner, where she processed adverse drug events, coded medical data, and ensured clinical studies adhered to good practices. She has strong analytical skills and a proven ability to meet timelines in challenging environments.
Safety & Regulatory Solutions for Small and Medium-sized Life Science Organiz...Covance
A key issue for small and medium-sized enterprises is the optimal utilization of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved product(s). This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement and globalization. Yet companies face overwhelming pressure to get their product to market as quickly as possible.
Overview - Use of e-Mail in Medical Practicealanbrookstone
The ability to communicate with one's physician has a number of potential benefits and inherent risks. This presentation outlines an approach towards the use of e-mail in medical practice.
ARRA & EMR Usability: What Providers Need to KnowJeffery Belden
What if US healthcare providers dramatically adopted EMRs in increasing numbers, worked hard to achieve meaningful use, but never benefited financially or in efficiency or quality?
Meaningful use will be dependent on adequate EMR usability. Discover how usability relates to a number of meaningful use criteria. We offer a usability checklist to assist providers in shopping for a new EMR, or to use during implementation of an existing EMR, in order to achieve efficiency, effectiveness, and usefulness.
Presentation to HIMSS 2010 with co-presenter Janey Barnes PhD.
Safety & Regulatory Solutions for Small and Medium-sized Life Science Organiz...Covance
A key issue for small and medium-sized enterprises is the optimal utilization of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved product(s). This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement and globalization. Yet companies face overwhelming pressure to get their product to market as quickly as possible.
Overview - Use of e-Mail in Medical Practicealanbrookstone
The ability to communicate with one's physician has a number of potential benefits and inherent risks. This presentation outlines an approach towards the use of e-mail in medical practice.
ARRA & EMR Usability: What Providers Need to KnowJeffery Belden
What if US healthcare providers dramatically adopted EMRs in increasing numbers, worked hard to achieve meaningful use, but never benefited financially or in efficiency or quality?
Meaningful use will be dependent on adequate EMR usability. Discover how usability relates to a number of meaningful use criteria. We offer a usability checklist to assist providers in shopping for a new EMR, or to use during implementation of an existing EMR, in order to achieve efficiency, effectiveness, and usefulness.
Presentation to HIMSS 2010 with co-presenter Janey Barnes PhD.
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies
General Manager and Executive Director of clinical studies conducted at ALS Inc.
PK expertise and extensive experience in clinical development of Phase 1 to 3 and bioequivalence studies.
Do you know how many rewarding job opportunities exist in the Clinical resea...Access-Pharma Jobs
If you are a BSc/MSc/PhD or MD/PharmD in career change, you can see some of the available career opportunities in the Clinical research industry and how to get in this field in this presentation made on Jan 14, 2017 at the Pharmacolloque 2017:
https://cra-school.com/news/
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
1. DOLORES M. Stadtmauer
Ocala, Florida
SUMMARY OF QUALIFICATIONS
More than twenty years of experience various Including ten years of solid
experience in the clinical drug development process Pharmaceutical and drug
safety. Major Strengths: a solid work ethic, a mind for analytical detail, and an
Ability to meet timelines in a challenging environment.
BUSINESS BACKGROUND
BRISTOL-MYERS SQUIBB COMPANY - HOPEWELL, NJ
Safety Regulatory Associate - Drug Safety & Pharmacovigilance GLOBAL &
Labeling 04/99 - 10/05
Possess detailed knowledge of all Adverse Event processing, e / g product
label / reaction assessment, medical coding and medical narrative writing
deferrals to the FDA. Processes broad volumes of Adverse Event (AE)
deferrals in GPV (Drives Performance, People Develops, Leads Strategically
energizes and Others). Queries Medical Directors and BMS in a Timely
Manner affiliates for clarification of deferrals to the FDA. (Builds Alignment,
Clearly Communicates). --other Supports teams in Adverse Event processing
(Collaborates).
Process Adverse Event boxes as Efficiently as possible, commensurate with
speed, quality, accuracy, and medical safety.
Assess whether an adverse event is listed there product's label; Code refer to
terms MEDRA: conduite and follow-up with the querying refer (s) to capture
additional relevant data.
Employed physicians as medical surveillance resource for spontaneous event
processing.
Trained our new (Over The Counter) Product Team members for clinical
studies and spontaneous reports.
Attended training classes for:
1. Micro Medex Training Seminar for Global Pharmacovigilance & Drug Safety
& Labeling.
2. Writing, Editing, and Proofreading.
3. Written Communication.
4. Communicating with Confidence
5. Medical Terminology (Continuing Education).
6. Global Pharmacovigilance & Drug Safety & Labeling - Scientific Writing.
7. Electronic Records, Electronic Signatures FDA Regulation (21 CFR Part 11).
2. Awards: Excellence Award Earned the Presidents
Dolores M. Stadtmauer - Page 2
BRISTOL-MYERS SQUIBB COMPANY - Plainsboro, NJ
Clinical Data Examiner - Data Management / Bio-Statistics 10/91 - 04/99
Data Management Project Leader overseeing the manufacture of clinical
studies from Beginning to end.
Perform processing of Serious Adverse Events, Codes for Medical Laboratory
Lab Normals, Co-start -CV, ONC,AIICNS, Lab tests, ICDA - Body systems &
Terms Primary dictionaries.
Perform quality data entry / validation, modification of clinical research data for
Post-Marketing III B and IV with the VAX / ORACLE IBBN Clintrial 4.1 Studies
and Clinical Systems on IBM VM / IMS Following in the therapeutic areas:
1. CNS - Central Nervous System
2. AI - Anti-Infective
3. CV - Cardiovascular
4. ONC - Oncology
Develop database design to multiple screen panel Produce / forms for the
VAX IBBN Clintrial 4.1 Clinical Studies Systems.
Prepare clinical data for input to the computer system.
Develop SAS programs to perform data integrity checks and generate
standard summary reports.
Work Closely with Statisticians, clinical monitors, and data management staff is
generation data management and processing queries.
Prepare for data entry queries to review the medical investigators at Their
clinical study site.
Updating status deferrals for outstanding queries.
Ensuring all activities adhere to Good Clinical Practices and règlements to
company standard operation procedures. Maintain master files and related
records of project documentation for Ongoing Projects.
Knowledge of Biomedical and Clinical Laboratory Tests Terminology / Lab
Normals.
Train clinical data processors in new projects.
Interview potential candidates.
Dolores M. Stadtmauer - Page 3
Training and Development Center
1. Good Clinical Practices.
3. 2. Clinical Data Management in Pharmaceutical Research and Development.
1. Leadership and Team Building Program.
1. Fundamental Presentation Skills.
1. Franklin Planner / Time Management Course.
2. Employee's Role in Career Development.
3. Medical Terminology Course in 1991.
4. Reading for Increased Productivity.
5. Listening for Increased Effectiveness.
6. Writing for Impact.
7. Vocabulary Power.
8. PDP - Phase I and II for Professional Development Support Staff
9. Enhancing Professional Image.
10. Break-it Thinking, Creative and Innovative Thinking / Critical Thinking
Relationship Skills
Dolores M. Stadtmauer - Page 4
Leadership Core BMS Behaviors / To our accountability for our results and
Behaviors. To build high-performance business That with The Highest Culture
of integrity and reach our goals. Our pledge to our customers, to our
colleagues, to our suppliers, to our Shareholders and to the Communities
Where We Live and Work, the countries Where We do business and the world
we serve.
Strategically Leads
Builds Alignment
Communicates Directly
Drives Performance
Collaborates
Energize Others
Develops People
Computer Training:
Microsoft Office
SAS Programming
R2W for Windows UNIX / N / T 5.20
Introduction to Unix and Shell Programming Language
PREVIOUS EMPLOYMENT
Details available on request
SUPREME COURT OF NEW JERSEY TO 8/88 10/91
Secretary for Legal Fee Arbitration Attorneys (Office of Attorney Ethics of the
Supreme Court of New Jersey)
4. Aries 2/84 to 7/88 Computing Corporation
Data Processing Consultant
President
EDUCATION
Irvington High School - Irvington, NJ - Graduated
Bergen Community College – Graduated